sees qtr-three earnings per share $num-one to $2.00.
sees fy non-gaap earnings per share $num-one to $num - two.
qtr-three adjusted earnings per share $num-two.
sees fy year-seven organic revenue growth of num-one% to num-two%.
sees fy year-six revenue $num-one million to $num - two million.
sees qtr-three revenue $num-one million to $3.0 billion.
qtrly organic revenue increased num-one%.
sees qtr-three sales $num-one million to $1.0 billion, below prior year guidance of $1 to $2.0 million.
sees qtr-three year-six total revenue growth of num-one% to num-two%.
qtrly revenue grew num-one% outside of us.
qtrly emerging market growth of num-one% versus prior year.
compname reports qtrly net income of $num-two million, up num-two% year-over-year.
qtrly free cash flow of $num-one billion, up num-two% from last year.
sees qtr-three organic revenue growth of num-one% to num-two%.
compname reports third quarter year-six results and announces num-one% increase in share repurchase authorization.
sees fy year-six neurosciences revenue growth of num-one% to num-two%.
